Clinical trial
A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
NCT02780180 is registered in ClinicalTrials.gov with Quantum Genomics SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
- Lead sponsor
- Quantum Genomics SA
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 30, 2016
- Completion date
- September 12, 2018
- Enrollment
- 23 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.